Trial Profile
A Retrospective study to evaluate the reasons for Secukinumab treatment discontinuation in patients with moderate to severe plaque psoriasis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2018
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- 09 May 2018 New trial record